SynGenSys Ltd. and Takeda Ventures, Inc. announce a strategic collaboration aimed at the development of novel cell-type specific synthetic promoters to support development of Takeda’s pipeline of innovative cell and gene therapies.
Professor David James, Chief Scientific Officer of SynGenSys: “This is an incredibly exciting opportunity for SynGenSys. We will work closely with Takeda to design new synthetic DNA components that provide targeted and controlled expression of therapeutic transgenes only where they are needed, avoiding non-specific cytotoxicity in non-diseased cells and tissues”.
“Takeda has established a world-class network of collaborators including a research partnership with Syngensys, where we are jointly leveraging our expertise to construct precision targeted gene therapy,” said Dr Victor Stone, Senior Investment Director and Partner, Takeda Ventures Inc. “Our collaboration and investment in Syngensys enables Takeda’s capabilities in synthetic promoters to advance next-generation gene therapies.”.
